In this study, we observed that intermediate CIN is linked to drug sensitivity according to three characteristics, including ER and HER2 status, the pre-existing level of CIN of the tumor cells, and the CIN induced by the treatments. This evidence concerns the gene ERBB2 and neoplasm.